Peptide derived from BOB1 protein presented by HLA-B*07:02

The "BOB1 peptide presented in HLA-B*07:02" refers to a short peptide fragment derived from the BOB1 (POU2AF1/OBF1) transcription factor, which is displayed on the cell surface in complex with the HLA-B*07:02 major histocompatibility complex class I molecule. This peptide–HLA complex is recognized by cytotoxic T cells and plays a critical role in immune surveillance against infected or malignant cells. The nature of the peptide, its affinity for HLA-B*07:02, and the presence of proline at the P2 anchor residue are essential for stable presentation[2][4][8]. While not a canonical drug target itself, specific peptide–HLA complexes are key targets in the development of cancer immunotherapies and can serve as biomarkers for precision immunotherapy approaches[5][7]. Note: - The entry as written ("BOB1 peptide presented in HLA-B*07:02") is not the standardized, canonical way to name such targets; a canonical form would specify the exact peptide sequence or refer to a broader class, such as "HLA-B*07:02–peptide complex" or, if focusing on source, "POU2AF1 (BOB1)–derived epitope in HLA-B*07:02." - Additional structured information (such as the exact peptide sequence and its immunogenicity) is needed for the most precise mapping and clinical utility[5][7]. If you can provide the **specific peptide sequence** or clarify which BOB1 epitope is meant, a more structured, canonical mapping can be generated.

Other names

POU2AF1OBF1

T cell recognition and killing of cells presenting the peptide–HLA complex (via TCR activation). Immune modulation (peptide vaccines or adoptive T cell therapies aim to boost CTL response against peptide–HLA complexes).